Upgrade to SI Premium - Free Trial

Vertex Pharma (VRTX)

472.57 -9.43 (1.96%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (8/3/26)

Latest Headlines

Form 4 VERTEX PHARMACEUTICALS For: Jul 15 Filed by: SACHS BRUCE I July 17, 2026 4:07 PM - SEC Filing Form 4 VERTEX PHARMACEUTICALS For: Jul 15 Filed by: Garber Alan M July 17, 2026 4:06 PM - SEC Filing Vortex Energy Provides Corporate Update on Robinsons River Salt Project Technical Study July 16, 2026 8:00 AM - Globe NewsWire Vertex (VRTX) PT Raised to $560 at Truist Securities July 13, 2026 7:08 AM - StreetInsider Stifel Downgrades Crinetics (CRNX) to Hold July 8, 2026 8:45 AM - StreetInsider H.C. Wainwright Reiterates Buy Rating on Vertex (VRTX) July 8, 2026 6:40 AM - StreetInsider Form 4 VERTEX PHARMACEUTICALS For: Jul 02 Filed by: Tatsis Ourania July 7, 2026 4:16 PM - SEC Filing Form 4 VERTEX PHARMACEUTICALS For: Jul 02 Filed by: McKechnie Duncan July 7, 2026 4:08 PM - SEC Filing Vertex to Announce Second Quarter 2026 Financial Results on August 3rd July 7, 2026 4:00 PM - BizWire Jones Trading Downgrades Crinetics (CRNX) to Hold July 7, 2026 9:27 AM - StreetInsider BMO Capital Reiterates Outperform Rating on Vertex (VRTX) July 7, 2026 8:49 AM - StreetInsider Vertex (VRTX) PT Raised to $570 at RBC Capital July 7, 2026 7:55 AM - StreetInsider Vertex (VRTX) Reiterated at Overweight by Cantor Fitzgerald; Crinetics Acquisition Announced July 7, 2026 7:16 AM - StreetInsider Canaccord Reiterates Hold Rating on Vertex (VRTX) July 7, 2026 6:58 AM - StreetInsider Form 8-K VERTEX PHARMACEUTICALS For: Jul 06 July 7, 2026 6:03 AM - SEC Filing Vertex Pharma (VRTX) call put ratio 1 call to 1.8 puts into acquiring Crinetics July 7, 2026 5:44 AM - StreetInsider Vertex (VRTX) PT Raised to $350 at Baird July 7, 2026 4:22 AM - StreetInsider Crinetics soars on $10B acquisition by Vertex July 6, 2026 4:14 PM - StreetInsider Form 4 VERTEX PHARMACEUTICALS For: Jul 01 Filed by: Liu Joy July 6, 2026 4:13 PM - SEC Filing Vertex to acquire Crinetics Pharmaceuticals for $10 billion July 6, 2026 4:04 PM - StreetInsider Vertex to Acquire Crinetics Pharmaceuticals July 6, 2026 4:04 PM - BizWire Vertex signs LoI with the Pan-Canadian Pharmaceutical Alliance for alyftrek for the treatment of cystic fibrosis July 6, 2026 10:25 AM - StreetInsider Form 144 VERTEX PHARMACEUTICALS Filed by: Tatsis Ourania July 2, 2026 4:31 PM - SEC Filing Form 144 VERTEX PHARMACEUTICALS Filed by: McKechnie Duncan July 2, 2026 2:16 PM - SEC Filing FDA expands Casgevy approval to children as young as 2 July 1, 2026 7:58 PM - StreetInsider Vertex Announces US FDA Approval for Expanded Use of CASGEVY® for the Treatment of People Ages 2 Years and Older With Sickle Cell Disease or Transfusion-Dependent Beta Thalassemia July 1, 2026 7:58 PM - BizWire FDA approves Casgevy gene therapy for sickle cell in children 2+ July 1, 2026 5:43 PM - StreetInsider Form 144 VERTEX PHARMACEUTICALS Filed by: Liu Joy July 1, 2026 1:00 PM - SEC Filing Form 4 VERTEX PHARMACEUTICALS For: Jun 26 Filed by: Bozic Carmen June 30, 2026 4:10 PM - SEC Filing Form 144 VERTEX PHARMACEUTICALS Filed by: Bozic Carmen June 26, 2026 9:55 AM - SEC Filing Form 4 VERTEX PHARMACEUTICALS For: Jun 18 Filed by: Bozic Carmen June 23, 2026 4:09 PM - SEC Filing Form 144 VERTEX PHARMACEUTICALS Filed by: Bozic Carmen June 18, 2026 11:33 AM - SEC Filing Form 4 VERTEX PHARMACEUTICALS For: Jun 15 Filed by: Bozic Carmen June 17, 2026 4:12 PM - SEC Filing Form 144 VERTEX PHARMACEUTICALS Filed by: Bozic Carmen June 15, 2026 3:08 PM - SEC Filing Leerink highlights drug demand rebound after Memorial Day June 12, 2026 2:42 PM - StreetInsider Vertex Presents New Data on CASGEVY®, Including First European Presentation of Data in Children Ages 5–11, at the European Hematology Association Congress and Announces Additional Global Regulatory June 11, 2026 2:01 AM - BizWire Form 4 VERTEX PHARMACEUTICALS For: Jun 05 Filed by: Bozic Carmen June 9, 2026 4:24 PM - SEC Filing Form 144 VERTEX PHARMACEUTICALS Filed by: Bozic Carmen June 5, 2026 2:33 PM - SEC Filing Vertex presents positive data for ALYFTREK in young cystic fibrosis patients June 5, 2026 12:05 PM - StreetInsider Vertex Presents New Data on ALYFTREK® at European Cystic Fibrosis Conference June 5, 2026 12:00 PM - BizWire Form 4 VERTEX PHARMACEUTICALS For: Jun 01 Filed by: Liu Joy June 3, 2026 4:07 PM - SEC Filing Vertex to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference on June 10 June 3, 2026 4:00 PM - BizWire Form 4 VERTEX PHARMACEUTICALS For: May 29 Filed by: Bozic Carmen June 2, 2026 4:04 PM - SEC Filing Form 144 VERTEX PHARMACEUTICALS Filed by: Liu Joy June 1, 2026 2:14 PM - SEC Filing Vertex gets FDA acceptance for IgA nephropathy drug application June 1, 2026 8:01 AM - StreetInsider Vertex Announces US FDA Acceptance of Biologics License Application for Accelerated Approval of Povetacicept in IgA Nephropathy June 1, 2026 8:00 AM - BizWire Form 144 VERTEX PHARMACEUTICALS Filed by: Bozic Carmen May 29, 2026 1:32 PM - SEC Filing JPMorgan says large-cap biotech is back as profits and pipelines fuel upside May 28, 2026 4:07 PM - StreetInsider Truist Securities Assumes Vertex (VRTX) at Buy May 27, 2026 1:02 AM - StreetInsider JPMorgan sees biotech sector at inflection point, resumes coverage on 14 Firms May 20, 2026 3:10 PM - StreetInsider JPMorgan Reinstates Vertex (VRTX) at Overweight May 20, 2026 4:30 AM - StreetInsider Form 4 VERTEX PHARMACEUTICALS For: May 15 Filed by: Bunnage Mark E. May 19, 2026 4:05 PM - SEC Filing Form 4 VERTEX PHARMACEUTICALS For: May 15 Filed by: Bozic Carmen May 19, 2026 4:04 PM - SEC Filing Form 144 VERTEX PHARMACEUTICALS Filed by: Bozic Carmen May 15, 2026 10:41 AM - SEC Filing Form 144 VERTEX PHARMACEUTICALS Filed by: Bunnage Mark E. May 15, 2026 10:02 AM - SEC Filing Form 4 VERTEX PHARMACEUTICALS For: May 12 Filed by: Bozic Carmen May 14, 2026 4:10 PM - SEC Filing Form SCHEDULE 13G/A VERTEX PHARMACEUTICALS Filed by: Capital World Investors May 14, 2026 1:56 PM - SEC Filing Form SCHEDULE 13G/A VERTEX PHARMACEUTICALS Filed by: Capital Research Global Investors May 14, 2026 10:20 AM - SEC Filing Form S-8 POS VERTEX PHARMACEUTICALS May 13, 2026 4:11 PM - SEC Filing Form S-8 POS VERTEX PHARMACEUTICALS May 13, 2026 4:10 PM - SEC Filing Form S-8 POS VERTEX PHARMACEUTICALS May 13, 2026 4:10 PM - SEC Filing Form S-8 POS VERTEX PHARMACEUTICALS May 13, 2026 4:10 PM - SEC Filing Form S-8 POS VERTEX PHARMACEUTICALS May 13, 2026 4:10 PM - SEC Filing Form S-8 POS VERTEX PHARMACEUTICALS May 13, 2026 4:10 PM - SEC Filing Form S-8 POS VERTEX PHARMACEUTICALS May 13, 2026 4:10 PM - SEC Filing Form S-8 VERTEX PHARMACEUTICALS May 13, 2026 4:08 PM - SEC Filing Form 8-K VERTEX PHARMACEUTICALS For: May 13 May 13, 2026 4:03 PM - SEC Filing Form 144 VERTEX PHARMACEUTICALS Filed by: Bozic Carmen May 12, 2026 1:12 PM - SEC Filing Vertex to Participate in Upcoming May Investor Conferences May 11, 2026 4:00 PM - BizWire BMO Capital Reiterates Market Perform Rating on Vertex (VRTX), 'positive steps' May 8, 2026 8:59 AM - StreetInsider Form 144 VERTEX PHARMACEUTICALS Filed by: Biller Jonathan May 6, 2026 2:14 PM - SEC Filing Vertex (VRTX) PT Raised to $615 at Barclays May 6, 2026 7:04 AM - StreetInsider Vertex secures German reimbursement for CASGEVY gene therapy May 6, 2026 7:01 AM - StreetInsider Vertex Announces CASGEVY® Reimbursement Agreement for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia in Germany May 6, 2026 7:01 AM - BizWire Form 4 VERTEX PHARMACEUTICALS For: May 01 Filed by: Upadhyay Suketu May 5, 2026 5:44 PM - SEC Filing Form 4 VERTEX PHARMACEUTICALS For: May 01 Filed by: Thornberry Nancy May 5, 2026 5:38 PM - SEC Filing Form 4 VERTEX PHARMACEUTICALS For: May 01 Filed by: Schneider Jennifer May 5, 2026 5:30 PM - SEC Filing Form 4 VERTEX PHARMACEUTICALS For: May 01 Filed by: SACHS BRUCE I May 5, 2026 5:25 PM - SEC Filing Form 4 VERTEX PHARMACEUTICALS For: May 01 Filed by: MCKENZIE DIANA May 5, 2026 5:18 PM - SEC Filing Form 4 VERTEX PHARMACEUTICALS For: May 01 Filed by: Liu Joy May 5, 2026 5:11 PM - SEC Filing Form 4 VERTEX PHARMACEUTICALS For: May 01 Filed by: Lagarde Michel May 5, 2026 5:07 PM - SEC Filing Form 4 VERTEX PHARMACEUTICALS For: May 01 Filed by: Garber Alan M May 5, 2026 4:59 PM - SEC Filing Form 4 VERTEX PHARMACEUTICALS For: May 01 Filed by: CARNEY LLOYD May 5, 2026 4:54 PM - SEC Filing Form 4 VERTEX PHARMACEUTICALS For: May 01 Filed by: Bhatia Sangeeta N. May 5, 2026 4:51 PM - SEC Filing Form 10-Q VERTEX PHARMACEUTICALS For: Mar 31 May 5, 2026 4:10 PM - SEC Filing Cantor Fitzgerald Reiterates Overweight Rating on Vertex (VRTX) Post Q1 Print May 5, 2026 9:26 AM - StreetInsider Vertex (VRTX) PT Raised to $616 at Morgan Stanley May 5, 2026 8:01 AM - StreetInsider Vertex (VRTX) PT Lowered to $436 at Canaccord May 5, 2026 7:06 AM - StreetInsider Vertex (VRTX) PT Raised to $543 at RBC Capital May 5, 2026 6:36 AM - StreetInsider Oppenheimer Reiterates Outperform Rating on Vertex (VRTX) May 5, 2026 6:06 AM - StreetInsider Vertex (VRTX) PT Lowered to $572 at Bernstein SocGen Group May 5, 2026 5:59 AM - StreetInsider Form 8-K VERTEX PHARMACEUTICALS For: May 04 May 4, 2026 4:06 PM - SEC Filing Vertex Pharma (VRTX) Tops Q1 EPS by 14c, Misses on Revenue; Offers FY26 Revenue Guidance May 4, 2026 4:03 PM - StreetInsider Vertex Reports First Quarter 2026 Financial Results May 4, 2026 4:01 PM - BizWire Form 144 VERTEX PHARMACEUTICALS Filed by: Bhatia Sangeeta N. May 4, 2026 10:18 AM - SEC Filing Form 144 VERTEX PHARMACEUTICALS Filed by: Liu Joy May 1, 2026 2:29 PM - SEC Filing Form SCHEDULE 13G VERTEX PHARMACEUTICALS Filed by: VANGUARD CAPITAL MANAGEMENT LLC April 30, 2026 2:30 PM - SEC Filing Vortex Energy Announces Intent to Advance Next Phase of Technical Work at the Robinsons River Salt Project and Engages Lonquist April 30, 2026 8:00 AM - Globe NewsWire Vertex (VRTX) PT Lowered to $437 at Canaccord April 30, 2026 6:35 AM - StreetInsider Form DEFA14A VERTEX PHARMACEUTICALS April 29, 2026 4:08 PM - SEC Filing Form 8-K VERTEX PHARMACEUTICALS For: Apr 28 April 29, 2026 4:05 PM - SEC Filing U.S. Biotech stocks: Q1 earnings previews April 26, 2026 8:00 PM - StreetInsider Vertex (VRTX) PT Lowered to $14 at BMO Capital April 24, 2026 8:32 AM - StreetInsider H.C. Wainwright Reiterates Buy Rating on Vertex (VRTX) April 23, 2026 6:58 AM - StreetInsider Full Article List